IRLAB-ANasdaq StockholmHealth CareIFRS · SEK

IRLAB Therapeutics

IRLAB Therapeutics is a Swedish biopharmaceutical company focused on discovering and developing novel treatments for Parkinson's disease and other central nervous system (CNS) disorders. Originating from Nobel Prize-winning research, the company leverages its proprietary Integrative Screening Process (ISP) to create first-in-class drug candidates. IRLAB's pipeline includes several promising compounds targeting different stages and symptoms of Parkinson's, with the potential to significantly improve patient outcomes. The company is listed on the Nasdaq Stockholm and is recognized for its strategic focus on CNS disorders.

Ask about the company
Revenue57.5m SEK
−39.3 %y/y
Operating profit (EBIT)-93.4m SEK
−24.3 %y/y
EBIT margin-162.5%
−83.2 ppy/y
Net income-110m SEK
−32.3 %y/y

Fiscal year 2025 · change from previous year

Development 2021–2025

-200-1000100200300m SEK2021: 208 m SEK2021: EBIT 53 m SEK20212022: 61 m SEK2022: EBIT -113 m SEK20222023: 5.7 m SEK2023: EBIT -181 m SEK20232024: 95 m SEK2024: EBIT -75 m SEK20242025: 57 m SEK2025: EBIT -93 m SEK202557-93
RevenueOperating profit (EBIT)
Ask Clarifo about IRLAB Therapeutics

Business

Share of revenue
Parkinson's Disease Treatments70 %

Includes drugs targeting various stages and symptoms of Parkinson's.

CNS Disorder Treatments20 %

Drugs for other central nervous system disorders beyond Parkinson's.

Research Platform Licensing10 %

Licensing of the proprietary ISP research platform.

Customers

IRLAB Therapeutics primarily serves the pharmaceutical and healthcare sectors, focusing on partnerships with large pharmaceutical companies and research institutions. Their customers include organizations seeking innovative treatments for Parkinson's and CNS disorders. The company's drug candidates are of interest to entities involved in clinical trials and those looking for licensing opportunities. IRLAB's unique research platform also attracts collaborations for drug discovery and development.

Pharmaceutical Companies

They buy drug candidates for CNS disorders to expand their treatment portfolios.

Research Institutions

They collaborate on clinical trials and research for Parkinson's treatments.

Licensing Partners

They license the ISP platform for drug discovery and development.

Strategy

IRLAB's strategic priorities include advancing its drug candidates through clinical trials, particularly focusing on mesdopetam and pirepemat. The company aims to secure strategic partnerships and collaborations to fund and support its R&D efforts. Another key priority is to expand its patent portfolio to protect its innovative treatments and extend market exclusivity. IRLAB is also focused on enhancing its proprietary ISP platform to continue generating first-in-class drug candidates.

Advance clinical trials for mesdopetamMedium term

To treat levodopa-induced dyskinesias effectively

Expand patent portfolioShort term

To protect innovations and extend exclusivity

Secure strategic partnershipsMedium term

To fund and support R&D efforts

Geography

IRLAB Therapeutics is headquartered in Gothenburg, Sweden, and operates primarily within the European market. The company is listed on the Nasdaq Stockholm, which provides it with a strong presence in the Nordic region. While its research and development activities are centered in Sweden, IRLAB collaborates internationally, particularly with regulatory bodies in the US and Europe for clinical trials. This geographic focus allows IRLAB to leverage regional expertise and regulatory frameworks to advance its drug candidates.

Risks

IRLAB faces several risks, including the inherent uncertainties of drug development, such as clinical trial failures and regulatory hurdles. The company is also exposed to financial risks due to its reliance on external funding and partnerships for R&D activities. Market competition from other CNS disorder treatments poses a threat to its market share. Additionally, changes in regulatory environments, particularly in the US and Europe, could impact the approval and commercialization of its drug candidates.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Clinical trial failures1Financial dependency2Regulatory hurdles3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Clinical trial failuresImpact: CriticalLikelihood: Medium

    Could delay or halt drug development

  2. Financial dependencyImpact: HighLikelihood: High

    Relies on external funding for R&D

  3. Regulatory hurdlesImpact: HighLikelihood: Low

    Impact approval and commercialization

Ask Clarifo about IRLAB Therapeutics

Accounting

Judgemental items
Revenue recognition

Affects reported income based on activity costs

Financial instruments valuation

No fair value measurements, affects comparability

Milestone payments timing

Leads to quarterly financial fluctuations

Similar listed companies

Publicly listed companies with a comparable business focus.

BioArctic

BIOA-B · Health Care

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

SciSparc Ltd.

SPRC · Pharmaceutical Preparations

Crispr Therapeutics AG

CRSP · Biological Products, (No Diagnostic Substances)

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

Relmada Therapeutics, Inc

RLMD · Pharmaceutical Preparations

Last updated: 24/09/2026